Cogstate net sales contracts hit $89M in FY26
Share
- Cogstate completed US$89 million in net sales contracts during the 2026 financial year.
- The company's share price finished down at $2.73 following the business update.
- The growth was driven by an expansion of total contracted future revenue to US$118.5 million.
Cogstate (ASX:CGS) executed US$89 million in full-year net sales contracts, representing a 116% increase over the previous year.
The growth contrasts with the US$41.3 million in net sales contracts executed by the business during the 2025 financial year.
The company stated that net sales contracts for the June quarter alone reached US$21.9 million.
Contracted future revenue entering the 2027 financial year expanded by 32% to US$118.5 million.
Following the announcement, the Cogstate share price was down at $2.73.
Of the contracted future revenue, the company expects to recognise US$48.3 million during the 2027 financial year.
The business noted that its contracted clinical trials revenue for the 2027 financial year reached US$46.1 million.
